Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012

SEOUL - South Korea's biosimilar front-runner Celltrion said it will push back the anticipated launch of biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to early 2012, instead of the original plan for a launch in the second half of 2011